Compare Humana Inc (HUM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs IDEXX Laboratories, Inc. — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $39.92B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.89% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HUM | IDXX | |
|---|---|---|
Market Cap | $47.61B | $39.92B |
Volume | 1,827,332 | 715,982 |
Sector | Health | Health |
52-Week High | $409.85 | $766.68 |
52-Week Low | $163.67 | $504.70 |
Typical Hold Time | 53 Days | 46 Days |
Enterprise Value | $54.97B | $40.82B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
IDEXX Laboratories (IDXX) trades at $513.14, down 0.44% with bearish technical signals despite strong fundamentals. The company demonstrates robust revenue growth, expanding from $3.4B in 2022 to $4.3B in 2025, with net income reaching $1.06B. Recent acquisitions like CoVetAI and diagnostic platform expansions highlight strategic growth initiatives. Technical indicators show oversold conditions with RSI at 26.58, while moving averages signal bearish momentum. Analyst consensus remains optimistic with a $665 price target representing 30% upside potential.
The outlook remains positive given strong earnings beats, expanding profit margins, and strategic acquisitions. However, risks include technical weakness, FX headwinds, and competitive pressures. With 56.5% analyst buy ratings and institutional accumulation, IDXX offers growth potential but requires monitoring of technical support levels near $492-$502 for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
